Keren Haruvi
Keren Haruvi

Keren Haruvi

President of Sandoz US and Head of North America

Keren Haruvi

President of Sandoz US and Head of North America

Keren Haruvi

Keren Haruvi is President of Sandoz US and Head of North America, leading Sandoz’ largest commercial and country organization – the United States – as well as Canada. Keren was appointed to the role in 2021, and she is also a member of the Novartis Country Leadership Team and the Global Sandoz Executive Committee.

Prior to joining Sandoz, Keren served as Global Head of M&A at Novartis International AG between 2017 and 2020. Her career began at Teva Pharmaceutical Industries, most recently as Senior VP, Global Business Development and Alliance Management.

Keren is a value creator in the biopharmaceutical space. She brings over 20 years of experience in the pharmaceutical industry marked by success leading major M&A deals, enterprise innovations, and complex market strategies for large-scale, sustainable growth. 

I live with a strong sense of urgency because life is happening in real-time and I don’t delay taking on a challenge or seizing an opportunity to provide and ask for feedback. Stepping up, managing and leading an organization – especially as we prepare to be a standalone company – takes focus, and mine is on growing an inclusive, diverse and entrepreneurial culture as we strive to increase our portfolio of generic and biosimilar medicines and support policies that improve patient access. My goal is for Sandoz to emerge as a stronger organization with an enhanced understanding of the needs of the diverse communities we serve.

Keren holds an MBA in Finance from Bar-Ilan University and Bachelor’s degrees in both Economics and Chemistry from Tel Aviv University. Outside of work, Keren enjoys spending time with her 5 children. She is an avid runner with one marathon and three half-marathons under her belt.

Nationality: Israeli | Year of birth: 1980

Professional experience

  • President, Sandoz US, Head of North America, Sandoz (2021 – present)
  • Global Head of M&A, Novartis (2017 – 2020)
  • SVP, Global Business Development and Alliance Management, Teva Pharmaceuticals (2016 – 2017)
  • SVP, Teva/Actavis Gx Integration Management Office, Teva Pharmaceuticals (2015 – 2016)
  • SVP, Head of M&A and Transactions Analytics, Global Business Development & Strategy, Teva Pharmaceuticals (2012 – 2015)
  • Director, Corporate Business Development, Teva Pharmaceuticals (2009 – 2012)
  • Analyst, Corporate Business Development, Teva Pharmaceuticals (2006 – 2009)
  • Manager, Business Development International Group, Teva Pharmaceuticals (2003 – 2006)


  • Board Member, Association of Accessible Medicines, Biosimilars Council Sponsor
  • Board Member, Taliaz


  • MBA, Finance, Bar-Ilan University, Ramat Gan
  • Bachelor of Arts in Economics, Tel Aviv University
  • Batchelor of Science in Chemistry, Tel Aviv University